Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi

Francesco Zaja; Flavia Salvi; Maura Rossi; Elena Sabattini; Andrea Evangelista; Giovannino Ciccone; Emanuele Angelucci; Gianluca Gaidano; Manuela Zanni; Marco Ladetto; Annalisa Chiappella; Umberto Vitolo; Pier Luigi Zinzani; Catello Califano; Alessandra Tucci; Caterina Patti; Stefano A. Pileri; Valentina Lenti; Pier Paolo Piccaluga; Federica Cavallo; Stefano Volpetti; Giulia Perali; Sarit Assouline; Koren Kathleen Mann; Ryan Morin; Miguel Alcaide; Kevin Bushell; Renato Fanin; Alessandro Levis

doi:10.1080/10428194.2018.1452208

Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi

Francesco Zaja
, Flavia Salvi
, Maura Rossi
, Elena Sabattini
, Andrea Evangelista
, Giovannino Ciccone
, Emanuele Angelucci
, Gianluca Gaidano
, Manuela Zanni
, Marco Ladetto
, Annalisa Chiappella
, Umberto Vitolo
, Pier Luigi Zinzani
, Catello Califano
, Alessandra Tucci
, Caterina Patti
, Stefano A. Pileri
, Valentina Lenti
, Pier Paolo Piccaluga
, Federica Cavallo

Stefano Volpetti, Giulia Perali, Sarit Assouline, Koren Kathleen Mann, Ryan Morin, Miguel Alcaide, Kevin Bushell, Renato Fanin, Alessandro Levis

Department of Translational Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

We investigated panobinostat 40 mg three times weekly in 35 adult patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Overall response rate and complete response were 17.1% and 11.4%, respectively. Median progression-free survival (PFS) and overall survival were 2.4 and 7.6 months, respectively. Calculated 12, 24 and 36 months PFS were 26%, 11% and 11%, respectively. Four patients who achieved a sustained CR, continued receiving panobinostat for an overall period of 44, 48, 50, 62 months. Thrombocytopenia grade 3 (5 patients) and 4 (24 patients) represented the main toxic effect, causing dose reduction or treatment suspension in 19 patients. Genomic analysis was unable to identify any relationship between mutations and response; TP53 mutation appeared not to impact the clinical outcome. Overall, panobinostat has a modest activity in R/R DLBCL patients, however it can induce very long lasting responses in some cases. Thrombocytopenia frequently limits the use of this agent.

Original language	English
Pages (from-to)	2904-2910
Number of pages	7
Journal	Leukemia and Lymphoma
Volume	59
Issue number	12
DOIs	https://doi.org/10.1080/10428194.2018.1452208
Publication status	Published - 2 Dec 2018

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Diffuse large B-cell lymphoma
genomic
panobinostat
relapsed/refractory

Access to Document

10.1080/10428194.2018.1452208

Cite this

Zaja, F., Salvi, F., Rossi, M., Sabattini, E., Evangelista, A., Ciccone, G., Angelucci, E., Gaidano, G., Zanni, M., Ladetto, M., Chiappella, A., Vitolo, U., Zinzani, P. L., Califano, C., Tucci, A., Patti, C., Pileri, S. A., Lenti, V., Piccaluga, P. P., ... Levis, A. (2018). Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi. Leukemia and Lymphoma, 59(12), 2904-2910. https://doi.org/10.1080/10428194.2018.1452208

@article{b378fd361eb146adb2bcfe56ea28267b,

title = "Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi",

abstract = "We investigated panobinostat 40 mg three times weekly in 35 adult patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Overall response rate and complete response were 17.1\% and 11.4\%, respectively. Median progression-free survival (PFS) and overall survival were 2.4 and 7.6 months, respectively. Calculated 12, 24 and 36 months PFS were 26\%, 11\% and 11\%, respectively. Four patients who achieved a sustained CR, continued receiving panobinostat for an overall period of 44, 48, 50, 62 months. Thrombocytopenia grade 3 (5 patients) and 4 (24 patients) represented the main toxic effect, causing dose reduction or treatment suspension in 19 patients. Genomic analysis was unable to identify any relationship between mutations and response; TP53 mutation appeared not to impact the clinical outcome. Overall, panobinostat has a modest activity in R/R DLBCL patients, however it can induce very long lasting responses in some cases. Thrombocytopenia frequently limits the use of this agent.",

keywords = "Diffuse large B-cell lymphoma, genomic, panobinostat, relapsed/refractory",

author = "Francesco Zaja and Flavia Salvi and Maura Rossi and Elena Sabattini and Andrea Evangelista and Giovannino Ciccone and Emanuele Angelucci and Gianluca Gaidano and Manuela Zanni and Marco Ladetto and Annalisa Chiappella and Umberto Vitolo and Zinzani, \{Pier Luigi\} and Catello Califano and Alessandra Tucci and Caterina Patti and Pileri, \{Stefano A.\} and Valentina Lenti and Piccaluga, \{Pier Paolo\} and Federica Cavallo and Stefano Volpetti and Giulia Perali and Sarit Assouline and Mann, \{Koren Kathleen\} and Ryan Morin and Miguel Alcaide and Kevin Bushell and Renato Fanin and Alessandro Levis",

note = "Publisher Copyright: {\textcopyright} 2018, {\textcopyright} 2018 Informa UK Limited, trading as Taylor \& Francis Group.",

year = "2018",

month = dec,

day = "2",

doi = "10.1080/10428194.2018.1452208",

language = "English",

volume = "59",

pages = "2904--2910",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Taylor and Francis Ltd.",

number = "12",

}

Zaja, F, Salvi, F, Rossi, M, Sabattini, E, Evangelista, A, Ciccone, G, Angelucci, E, Gaidano, G, Zanni, M, Ladetto, M, Chiappella, A, Vitolo, U, Zinzani, PL, Califano, C, Tucci, A, Patti, C, Pileri, SA, Lenti, V, Piccaluga, PP, Cavallo, F, Volpetti, S, Perali, G, Assouline, S, Mann, KK, Morin, R, Alcaide, M, Bushell, K, Fanin, R & Levis, A 2018, 'Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi', Leukemia and Lymphoma, vol. 59, no. 12, pp. 2904-2910. https://doi.org/10.1080/10428194.2018.1452208

Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi. / Zaja, Francesco; Salvi, Flavia; Rossi, Maura et al.
In: Leukemia and Lymphoma, Vol. 59, No. 12, 02.12.2018, p. 2904-2910.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma

T2 - clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi

AU - Zaja, Francesco

AU - Salvi, Flavia

AU - Rossi, Maura

AU - Sabattini, Elena

AU - Evangelista, Andrea

AU - Ciccone, Giovannino

AU - Angelucci, Emanuele

AU - Gaidano, Gianluca

AU - Zanni, Manuela

AU - Ladetto, Marco

AU - Chiappella, Annalisa

AU - Vitolo, Umberto

AU - Zinzani, Pier Luigi

AU - Califano, Catello

AU - Tucci, Alessandra

AU - Patti, Caterina

AU - Pileri, Stefano A.

AU - Lenti, Valentina

AU - Piccaluga, Pier Paolo

AU - Cavallo, Federica

AU - Volpetti, Stefano

AU - Perali, Giulia

AU - Assouline, Sarit

AU - Mann, Koren Kathleen

AU - Morin, Ryan

AU - Alcaide, Miguel

AU - Bushell, Kevin

AU - Fanin, Renato

AU - Levis, Alessandro

PY - 2018/12/2

Y1 - 2018/12/2

N2 - We investigated panobinostat 40 mg three times weekly in 35 adult patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Overall response rate and complete response were 17.1% and 11.4%, respectively. Median progression-free survival (PFS) and overall survival were 2.4 and 7.6 months, respectively. Calculated 12, 24 and 36 months PFS were 26%, 11% and 11%, respectively. Four patients who achieved a sustained CR, continued receiving panobinostat for an overall period of 44, 48, 50, 62 months. Thrombocytopenia grade 3 (5 patients) and 4 (24 patients) represented the main toxic effect, causing dose reduction or treatment suspension in 19 patients. Genomic analysis was unable to identify any relationship between mutations and response; TP53 mutation appeared not to impact the clinical outcome. Overall, panobinostat has a modest activity in R/R DLBCL patients, however it can induce very long lasting responses in some cases. Thrombocytopenia frequently limits the use of this agent.

AB - We investigated panobinostat 40 mg three times weekly in 35 adult patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Overall response rate and complete response were 17.1% and 11.4%, respectively. Median progression-free survival (PFS) and overall survival were 2.4 and 7.6 months, respectively. Calculated 12, 24 and 36 months PFS were 26%, 11% and 11%, respectively. Four patients who achieved a sustained CR, continued receiving panobinostat for an overall period of 44, 48, 50, 62 months. Thrombocytopenia grade 3 (5 patients) and 4 (24 patients) represented the main toxic effect, causing dose reduction or treatment suspension in 19 patients. Genomic analysis was unable to identify any relationship between mutations and response; TP53 mutation appeared not to impact the clinical outcome. Overall, panobinostat has a modest activity in R/R DLBCL patients, however it can induce very long lasting responses in some cases. Thrombocytopenia frequently limits the use of this agent.

KW - Diffuse large B-cell lymphoma

KW - genomic

KW - panobinostat

KW - relapsed/refractory

UR - https://www.scopus.com/pages/publications/85044938873

U2 - 10.1080/10428194.2018.1452208

DO - 10.1080/10428194.2018.1452208

M3 - Article

SN - 1042-8194

VL - 59

SP - 2904

EP - 2910

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 12

ER -

Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this